Medgenics Raises $46M In Secondary NYSE Offering

October 14, 2015 | Israeli bio-medical company, Medgenics closed its secondary share offering, raising $46 million. The Galilee-based company opted to issue more shares after its share price climbed over 50% between January and September of this year. Currently, the company’s market capitalization is $236 million. Founded in 2000 and led by CEO Michael Cola, Medgenics is developing a technology platform called TARGT that will help to treat patients with rare and orphan diseases.